Tricida (TCDA) Misses Q1 EPS by 1c

Tricida (NASDAQ: TCDA) reported Q1 EPS of ($0.78), $0.01 worse than the analyst estimate of ($0.77).

“With the completion of our successful long-term extension trial, we are now focused on the NDA submission in the second half of this year under the Accelerated Approval Program,” said Gerrit Klaerner, Ph.D., Tricida’s Chief Executive Officer and President. “We are also keenly focused on our prelaunch activities, in particular in advancing disease education and awareness of the central role metabolic acidosis plays in exacerbating bone, muscle and kidney disease.”

For earnings history and earnings-related data on Tricida (TCDA) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Vivos Therapeutics posts 35% revenue gain but widens net loss
• Star Equity Holdings (STRR) Misses Q2 EPS by 8c